- Home
- LYEL
LYEL
Lyell Immunopharma Inc.
as 11-21-2024 4:00pm EST
| Founded: | 2018 | Country: | United States |
| Employees: | N/A | City: | SOUTH SAN FRANCISCO |
| Market Cap: | N/A | IPO Year: | 2021 |
| Target Price: | $1.00 | AVG Volume (30 days): | 2.3M |
| Analyst Decision: | Sell | Number of Analysts: | 2 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.80 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.85 - $3.26 | Next Earning Date: | 11-07-2024 |
| Revenue: | $63,000 | Revenue Growth: | -99.87% |
| Revenue Growth (this year): | -93.72% | Revenue Growth (next year): | N/A |
Latest Lyell Immunopharma Inc. News
LYEL Breaking Stock News: Dive into LYEL Ticker-Specific Updates for Smart Investing
Zacks
7 days ago
Lyell Immunopharma (LYEL) Upgraded to Buy: Here's What You Should Know
Associated Press Finance
14 days ago
Lyell Immunopharma: Q3 Earnings Snapshot
GlobeNewswire
14 days ago
Lyell Immunopharma Reports Business Highlights and Financial Results for the Third Quarter 2024
GlobeNewswire
16 days ago
Lyell Announces Presentation of Initial Clinical Data from the Phase 1-2 Clinical Trial of IMPT-314 for the treatment of B-cell Lymphoma at the 2024 American Society of Hematology (ASH) Annual Meeting
Simply Wall St.
20 days ago
LiveOne Leads The Pack Of 3 US Penny Stocks
GlobeNewswire
21 days ago
Lyell Immunopharma Completes Acquisition of ImmPACT Bio
MT Newswires
22 days ago
Lyell Immunopharma Shares Fall After BofA Downgrade
Investing.com
22 days ago
Lyell shares down as BofA double downgrades to Sell
Compare LYEL vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "LYEL Lyell Immunopharma Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.